Schizophrenia 9

Categories: Genetic diseases, Mental diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Schizophrenia 9

MalaCards integrated aliases for Schizophrenia 9:

Name: Schizophrenia 9 54 71 29 69
Schizophrenia Susceptibility Locus Chromosome 1q-Related 71
Sczd9 71


External Ids:

OMIM 54 604906
MedGen 40 C1858050
MeSH 42 D012559

Summaries for Schizophrenia 9

UniProtKB/Swiss-Prot : 71 Schizophrenia 9: A complex, multifactorial psychotic disorder or group of disorders characterized by disturbances in the form and content of thought (e.g. delusions, hallucinations), in mood (e.g. inappropriate affect), in sense of self and relationship to the external world (e.g. loss of ego boundaries, withdrawal), and in behavior (e.g bizarre or apparently purposeless behavior). Although it affects emotions, it is distinguished from mood disorders in which such disturbances are primary. Similarly, there may be mild impairment of cognitive function, and it is distinguished from the dementias in which disturbed cognitive function is considered primary. Some patients manifest schizophrenic as well as bipolar disorder symptoms and are often given the diagnosis of schizoaffective disorder.

MalaCards based summary : Schizophrenia 9, also known as schizophrenia susceptibility locus chromosome 1q-related, is related to bladder flat intraepithelial lesion and chronic conjunctivitis. An important gene associated with Schizophrenia 9 is DISC1 (Disrupted In Schizophrenia 1). The drugs Citalopram and Reboxetine have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and tongue.

Description from OMIM: 604906

Related Diseases for Schizophrenia 9

Diseases in the Schizophrenia family:

Schizophrenia 9 Schizophrenia 17
Schizophrenia 16 Schizophrenia 10
Schizophrenia 19 Schizophrenia 4
Schizophrenia 15 Early-Onset Schizophrenia

Diseases related to Schizophrenia 9 via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 bladder flat intraepithelial lesion 9.6 DISC1 RGS4
2 chronic conjunctivitis 9.5 DISC1 RGS4
3 bone fracture 9.4 DISC1 RGS4
4 schizophrenia 9.2 DISC1 RGS4

Symptoms & Phenotypes for Schizophrenia 9

Clinical features from OMIM:


Drugs & Therapeutics for Schizophrenia 9

Drugs for Schizophrenia 9 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 187)
id Name Status Phase Clinical Trials Cas Number PubChem Id
Citalopram Approved Phase 4 59729-33-8 2771
Reboxetine Approved, Investigational Phase 4 98769-81-4, 71620-89-8 123628 65856
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 106266-06-2 5073
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 132539-06-1 4585
Histamine Approved, Investigational Phase 4,Phase 2,Phase 3 75614-87-8, 51-45-6 774
Nizatidine Approved Phase 4 76963-41-2 3033637
Clozapine Approved Phase 4,Phase 1 5786-21-0 2818
Mianserin Approved Phase 4 24219-97-4 4184
Mirtazapine Approved Phase 4 85650-52-8, 61337-67-5 4205
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 129722-12-9 60795
Haloperidol Approved Phase 4,Phase 3,Phase 2,Phase 1 52-86-8 3559
Lorazepam Approved Phase 4 846-49-1 3958
Allopurinol Approved Phase 4 315-30-0 2094
Ziprasidone Approved Phase 4,Phase 3,Phase 2,Phase 1 146939-27-7 60854
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
Nicotine Approved Phase 4,Phase 2,Phase 3 54-11-5 942 89594
Benzocaine Approved Phase 4 1994-09-7, 94-09-7 2337
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
leucovorin Approved, Nutraceutical Phase 4 58-05-9 143 6006
23 tannic acid Approved, Nutraceutical Phase 4
24 Adrenergic Agents Phase 4,Phase 2
25 Antidepressive Agents Phase 4,Phase 1
26 Antidepressive Agents, Second-Generation Phase 4,Phase 1
27 Antiparkinson Agents Phase 4,Phase 3,Phase 2,Phase 1
28 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Phase 1
29 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
30 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
31 Cholinergic Agents Phase 4,Phase 2
32 Cholinergic Antagonists Phase 4
33 Muscarinic Antagonists Phase 4
34 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
35 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
36 Parasympatholytics Phase 4
37 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
38 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1
Serotonin Phase 4,Phase 3,Phase 2,Phase 1 50-67-9 5202
40 Serotonin Agents Phase 4,Phase 3,Phase 2,Phase 1
41 Serotonin Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
42 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1
43 Anti-Bacterial Agents Phase 4,Phase 1
44 Anti-Infective Agents Phase 4,Phase 3,Phase 1
45 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
46 Dopamine Antagonists Phase 4,Phase 3,Phase 2,Phase 1
47 Dopamine D2 Receptor Antagonists Phase 4,Phase 3,Phase 2,Phase 1
48 Paliperidone Palmitate Phase 4,Phase 3,Phase 2,Phase 1
49 Serotonin 5-HT2 Receptor Antagonists Phase 4,Phase 3,Phase 2,Phase 1
50 Serotonin Antagonists Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 193)

id Name Status NCT ID Phase Drugs
1 Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia Unknown status NCT01300364 Phase 4 Reboxetine;citalopram (SSRI)
2 Minocycline as an Adjunctive Therapy for Schizophrenia: a Randomized Controlled Study Unknown status NCT01133080 Phase 4 Minocycline;placebo
3 Tolerability And Efficacy Of High Dose Escitalopram In The Treatment Of Patients Suffering From Schizophrenia And Obsessive-Compulsive Disorder (OCD) - An Open Label Study Unknown status NCT00708396 Phase 4 Escitalopram
4 Early Prediction of Clinical Response in Patients With Schizophrenia Treated by Paliperidone ER Completed NCT02075528 Phase 4 Paliperidone ER
5 Safety and Efficacy Study of Paliperidone Extended Release (ER) Among Thai Schizophrenia Participants Completed NCT01387542 Phase 4 Paliperidone extended release (ER)
6 Study to Measure Drug Satisfaction of Patients With Schizophrenia After Switching From Risperidone to Paliperidone Completed NCT00535132 Phase 4 Oral Risperidone;Paliperidone ER
7 Paliperidone Extended Release(ER) Effectiveness Study to Evaluate the Objective Symptom Change and Symptomatic Remission Completed NCT00761579 Phase 4 Paliperidone
8 Managing Acute Schizophrenia, a Comparison Between Two Atypical Antipsychotics Completed NCT00485498 Phase 4 Olanzapine Hydrochloride;Risperidone
9 Weight Gain Management in Patients With Schizophrenia Completed NCT00486005 Phase 4 Olanzapine Hydrochloride;Nizatidine;Placebo
10 CARE Study: Improving Treatment for the Most Severely Ill With Schizophrenia Completed NCT00272584 Phase 4 Risperidone
11 Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder Completed NCT00190749 Phase 4 olanzapine;risperidone
12 Assessment of a Weight Management Program for Weight Gain in Patients With Schizophrenia Completed NCT00485823 Phase 4 Olanzapine Hydrochloride
13 Evaluation of Mirtazapine and Folic Acid for Schizophrenia: Completed NCT01263080 Phase 4 mirtazapine;folic acid placebo;mirtazapine placebo;folic acid
14 Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia Completed NCT00103571 Phase 4 Olanzapine;Aripiprazole
15 Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia Completed NCT00088049 Phase 4 Olanzapine;Aripiprazole
16 Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder Completed NCT00100776 Phase 4 Olanzapine
17 Study in Adolescents With Schizophrenia or Bipolar Disorder Completed NCT00982020 Phase 4 Olanzapine
18 Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder Completed NCT00090012 Phase 4 Olanzapine;Quetiapine
19 Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia Completed NCT00337662 Phase 4 olanzapine;risperidone;risperidone
20 Efficacy Study of Switching Stabilized Schizophrenic Patients From Conventional to Atypical Antipsychotic Treatment Completed NCT00191555 Phase 4 olanzapine;haloperidol
21 The Significance of Deviation in Time From the 12-hour Standard Serum-clozapine Monitoring. Completed NCT02625103 Phase 4 Clozapine
22 Patient's Preference Between Conventional Oral Olanzapine Tablet vs Olanzapine Orodispersible Tablet Completed NCT00324051 Phase 4 olanzapine therapy
23 Comparing the Effect of Under the Tongue Olanzapine Versus Swallowed Olanzapine on Body Mass Index (A Ratio of Weight to Height) Completed NCT00303602 Phase 4 Sublingual orally disintegrating olanzapine (SODO);Oral olanzapine
24 IMPACT: A Study to Explore the Efficacy and Safety of Paliperidone ER in Patients With Acute Agitation Completed NCT01050478 Phase 4 Paliperidone ER;Benzodiazepine
25 Clinical Effectiveness of Newer Antipsychotics in Comparison With Conventional Antipsychotics in Schizophrenia Completed NCT01164059 Phase 4 Olanzapine;Flupentixol;Quetiapine;Aripiprazole;Haloperidol
26 Allopurinol in Schizophrenia: A Randomized Trial Administering Allopurinol vs Placebo as add-on Antipsychotics in Patients With Schizophrenia Completed NCT00864825 Phase 4 Allopurinol
27 A Study on Induced Weight Gain During Atypical Antipsychotic Treatment and Its Management With Psychoeducational Programme Completed NCT00191828 Phase 4 olanzapine
28 Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 1-year Follow-up Completed NCT02534363 Phase 4 Aripiprazole;Quetiapine;Ziprasidone
29 Paroxetine - Controlled Release in the Treatment of Irritable Bowel Syndrome (IBS) Completed NCT00610909 Phase 4 Paroxetine CR;Placebo
30 Safety and Effectiveness of Sustained Release Bupropion in Treating Individuals With Schizophrenia Who Smoke Completed NCT00307203 Phase 4 bupropion SR;nicotine replacement therapy
31 Observational Study to Assess Outcomes During Antipsychotic Treatment With Paliperidone ER or Other Oral Antipsychotics Completed NCT00696813 Phase 4
32 A Pharmacokinetic Study of Paliperidone ER Recruiting NCT02433717 Phase 4 Paliperidone ER
33 European Long-acting Antipsychotics in Schizophrenia Trial Recruiting NCT02146547 Phase 4 Aripiprazole;Aripiprazole depot;Paliperidone;Paliperidone palmitate
34 Assessment of Adverse Events in a Naive Pediatric Population Treated With an Antipsychotic Active, not recruiting NCT02007928 Phase 4
35 A Positron-Emission-Tomography (PET) Study to Measure the Blockade of Dopamine Receptors (D2) in Specific Areas of the Brain in Relation to the Plasma Concentrations of Paliperidone Extended Release (ER) and Oral Risperidone in Schizophrenia Patients and Terminated NCT00934635 Phase 4 Paliperidone ER;Oral risperidone;Oral risperidone;Oral risperidone;Paliperidone ER;Paliperidone ER;Oral risperidone;Paliperidone ER
36 28-30 Month Study Comparing Paliperidone Palmitate With Oral Risperidone for Treating Adults Diagnosed With Schizophrenia Within the Past 5 Years Terminated NCT00946985 Phase 4 paliperidone palmitate;oral risperidone
37 Trial Evaluating Three Fixed Dosages of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia Completed NCT00078039 Phase 3 Paliperidone ER
38 A 52-week, Open-label Extension Study Following a 6-week, Double-blind, Placebo- and Active- Controlled Study (R076477-SCH-303) to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia Completed NCT00650793 Phase 3 Extended Release OROS® Paliperidone
39 An Open Label Multicentre Study to Determine the Dose Distribution of Paliperidone ER in Patients With Schizophrenia Completed NCT00473434 Phase 3 Paliperidone
40 Cariprazine Relative to Placebo in the Prevention of Relapse of Symptoms in Patients With Schizophrenia Completed NCT01412060 Phase 3 Cariprazine;Placebo
41 A 6 Month Study to Compare the Metabolic Effects of Paliperidone ER and Olanzapine in Patients With Schizophrenia Completed NCT00645099 Phase 3 olanzapine;paliperidone ER
42 An Efficacy and Safety Study of Extended-Release (ER) Paliperidone in Adolescent Participants With Schizophrenia Completed NCT01009047 Phase 3 Paliperidone extended release (ER);Aripiprazole
43 Comparison of Intramuscular Olanzapine and Intramuscular Haloperidol in Patients With Schizophrenia Completed NCT00485901 Phase 3 Olanzapine Hydrochloride;Haloperidol
44 Trial Evaluating Three Fixed Doses of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia Completed NCT00083668 Phase 3 Paliperidone ER
45 Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia Completed NCT00589914 Phase 3 RISPERDAL CONSTA;Paliperidone palmitate
46 Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in Patients With Schizophrenia Completed NCT00088491 Phase 3 Intramuscular Olanzapine Depot;Oral Olanzapine
47 Long-Acting Injectable Risperidone in the Treatment of Schizophrenia Completed NCT00132314 Phase 3 IM risperidone;oral antipsychotic medication
48 A Study of Flexibly Dosed Paliperidone Extended Release Tablets in Participants With Schizophrenia Completed NCT01541371 Phase 3 Paliperidone ER
49 A Physical Dependence Study in Schizophrenia Completed NCT01452919 Phase 3 LY2140023;Placebo
50 Olanzapine Versus Placebo in the Treatment of Adolescents With Schizophrenia Completed NCT00051298 Phase 3 Olanzapine;Placebo

Search NIH Clinical Center for Schizophrenia 9

Genetic Tests for Schizophrenia 9

Genetic tests related to Schizophrenia 9:

id Genetic test Affiliating Genes
1 Schizophrenia 9 29

Anatomical Context for Schizophrenia 9

MalaCards organs/tissues related to Schizophrenia 9:

Testes, Brain, Tongue

Publications for Schizophrenia 9

Variations for Schizophrenia 9

Expression for Schizophrenia 9

Search GEO for disease gene expression data for Schizophrenia 9.

Pathways for Schizophrenia 9

GO Terms for Schizophrenia 9

Sources for Schizophrenia 9

9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
52 Novoseek
55 OMIM via Orphanet
59 PubMed
66 SNOMED-CT via Orphanet
68 Tocris
70 UMLS via Orphanet
Loading form....